Thomas Meier Appointed as New CEO of Medios AG, Signaling Strategic Growth Push in European Specialty Pharma

The Supervisory Board of Medios AG has appointed Thomas Meier as the new Chief Executive Officer effective February 1, 2026, marking a significant leadership transition for the German specialty pharmaceutical company. Meier succeeds Matthias Gaertner, who will remain in office until December 31, 2025, concluding a ten-year tenure that saw substantial growth and development of the company.

Thomas Meier brings extensive international experience to Medios AG, having served as CEO of Swiss Contract Development and Manufacturing Organization Bachem Holding AG since 2020. His background includes previous roles as Chief Operations Officer on Bachem's Executive Board and as Head of Manufacturing at Peninsula Laboratories in San Carlos, California from 2001 to 2004. This appointment signals Medios' commitment to strengthening its position in the competitive European pharmaceutical landscape.

Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG, emphasized the strategic importance of this leadership change. "With Thomas Meier, we are gaining an internationally experienced leader with a strong track record of capital-efficient, profitable growth," Samson stated. "We are convinced that his entrepreneurial spirit, expertise and leadership will contribute significantly to achieving our ambitious goals and sustainably increasing value for shareholders, partners, and customers."

The leadership transition comes at a critical time for Medios as the company positions itself for further expansion in the European Specialty Pharma market. Medios operates as Germany's first listed specialty pharmaceutical company, with shares traded on the Frankfurt Stock Exchange's Prime Standard and inclusion in the SDAX selection index. The company maintains operations across Germany, the Netherlands, Belgium and Spain, supporting partners throughout the pharmaceutical supply chain with innovative solutions and services.

Thomas Meier expressed enthusiasm for his new role, stating, "I am very much looking forward to the task of leading Medios into its next phase of development. Together with my colleagues on the Executive Board and the entire Medios team, I will continue to consistently develop the successful strategy and sustainably expand Medios' position in the European Specialty Pharma market."

This leadership appointment holds significance for the broader pharmaceutical industry as it reflects the growing importance of specialized pharmaceutical services in Europe. Medios has established itself as a pioneer in individualized medicine, working to make innovative therapies accessible through partnerships with pharmacies, specialist practices and pharmaceutical companies. More information about the company's approach to personalized healthcare can be found at https://app.medios.group/en/individualizedmedicine.

The timing of this announcement precedes several important corporate events for Medios in the 2025 financial year, including the Quarterly Statement as of September 30, 2025 on November 11, participation in the mwb inspired Conference in Hamburg on November 12, and the Berenberg European Conference at Fairmont Windsor Park in Great Britain on December 4. These events will provide stakeholders with additional insights into the company's strategic direction under new leadership.

For investors and industry observers, this CEO transition represents more than just a leadership change—it signals Medios' commitment to maintaining its competitive edge in the rapidly evolving specialty pharmaceutical sector. The appointment of an executive with Meier's international experience and proven track record in pharmaceutical manufacturing and development suggests the company is positioning itself for accelerated growth and expanded market presence across Europe.